Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Managing Director | Vertex Ventures HC
Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRL Ventures Fund (MRLV). She was previously on the board of Altimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Quartet Medicine and Viamet Pharmaceuticals. She is currently responsible for MRLV’s investments in Entrada Therapeutics, Alector (NASDAQ:ALEC) and Translate Bio (NASDAQ:TBIO). Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small biopharmaceutical and large pharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and did post-doctoral research in developmental neurobiology at the National Institutes of Health.

Brought to you by